61 related articles for article (PubMed ID: 34313188)
1. Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis.
Filippi R; Leone F; Fornaro L; Aprile G; Casadei-Gardini A; Silvestris N; Palloni A; Satolli MA; Scartozzi M; Russano M; Lutrino SE; Lombardi P; Frega G; Garattini SK; Vivaldi C; Spadi R; Giulia O; Fenocchio E; Brunetti O; Aglietta M; Brandi G
J Chemother; 2022 Apr; 34(2):123-132. PubMed ID: 34313188
[TBL] [Abstract][Full Text] [Related]
2. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
[TBL] [Abstract][Full Text] [Related]
3. Second-line Chemotherapy Prolongs Survival in Real World Patients With Advanced Biliary Tract and Gallbladder Cancers: A Multicenter Retrospective Population-based Cohort Study.
Zaidi A; Chandna N; Narasimhan G; Moser M; Haider K; Chalchal H; Shaw J; Ahmed S
Am J Clin Oncol; 2021 Mar; 44(3):93-98. PubMed ID: 33350678
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in patients receiving palliative chemotherapy for advanced biliary tract cancer.
Thol F; Gairing SJ; Czauderna C; Thomaidis T; Gamstätter T; Huber Y; Vollmar J; Lorenz J; Michel M; Bartsch F; Müller L; Kloeckner R; Galle PR; Wörns MA; Marquardt JU; Moehler M; Weinmann A; Foerster F
JHEP Rep; 2022 Mar; 4(3):100417. PubMed ID: 35141511
[TBL] [Abstract][Full Text] [Related]
5. Second-line chemotherapy in patients with advanced or recurrent biliary tract cancer: a single center, retrospective analysis of 294 cases.
Takahara N; Nakai Y; Isayama H; Sasaki T; Saito K; Oyama H; Kanai S; Suzuki T; Sato T; Hakuta R; Ishigaki K; Takeda T; Saito T; Mizuno S; Kogure H; Tada M; Koike K
Invest New Drugs; 2018 Dec; 36(6):1093-1102. PubMed ID: 30324343
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers.
Sebbagh S; Roux J; Dreyer C; Neuzillet C; de Gramont A; Orbegoso C; Hentic O; Hammel P; de Gramont A; Raymond E; André T; Chibaudel B; Faivre S
Acta Oncol; 2016; 55(9-10):1168-1174. PubMed ID: 27333436
[TBL] [Abstract][Full Text] [Related]
7. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
[TBL] [Abstract][Full Text] [Related]
8. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
9. Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.
Walter T; Horgan AM; McNamara M; McKeever L; Min T; Hedley D; Serra S; Krzyzanowska MK; Chen E; Mackay H; Feld R; Moore M; Knox JJ
Eur J Cancer; 2013 Jan; 49(2):329-35. PubMed ID: 22947649
[TBL] [Abstract][Full Text] [Related]
10. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
Furuse J; Okusaka T; Ohkawa S; Nagase M; Funakoshi A; Boku N; Yamao K; Yamaguchi T; Sato T
Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
[TBL] [Abstract][Full Text] [Related]
12. Multivariate prognostic factors analysis for second-line chemotherapy in advanced biliary tract cancer.
Fornaro L; Cereda S; Aprile G; Di Girolamo S; Santini D; Silvestris N; Lonardi S; Leone F; Milella M; Vivaldi C; Belli C; Bergamo F; Lutrino SE; Filippi R; Russano M; Vaccaro V; Brunetti AE; Rotella V; Falcone A; Barbera MA; Corbelli J; Fasola G; Aglietta M; Zagonel V; Reni M; Vasile E; Brandi G
Br J Cancer; 2014 Apr; 110(9):2165-9. PubMed ID: 24714745
[TBL] [Abstract][Full Text] [Related]
13. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
[TBL] [Abstract][Full Text] [Related]
14. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
15. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
16. Comparison of FOLFIRINOX Chemotherapy with Other Regimens in Patients with Biliary Tract Cancers: a Retrospective Study.
Kus T; Aktas G; Kalender ME; Sevinc A; Camci C
J Gastrointest Cancer; 2017 Jun; 48(2):170-175. PubMed ID: 27714651
[TBL] [Abstract][Full Text] [Related]
17. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
18. Glasgow Prognostic Score predicts poor prognosis among advanced biliary tract cancer patients with good performance status.
Moriwaki T; Ishige K; Araki M; Yoshida S; Nishi M; Sato M; Yamada T; Yamamoto Y; Ozeki M; Ishida H; Yamaguchi T; Matsuda K; Murashita T; Abei M; Hyodo I
Med Oncol; 2014 Nov; 31(11):287. PubMed ID: 25316268
[TBL] [Abstract][Full Text] [Related]
19. New developments in systemic therapy for advanced biliary tract cancer.
Morizane C; Ueno M; Ikeda M; Okusaka T; Ishii H; Furuse J
Jpn J Clin Oncol; 2018 Aug; 48(8):703-711. PubMed ID: 29893894
[TBL] [Abstract][Full Text] [Related]
20. Second-line Treatment in Advanced Biliary Tract Cancer: Today and Tomorrow.
Rizzo A; Ricci AD; Tober N; Nigro MC; Mosca M; Palloni A; Abbati F; Frega G; DE Lorenzo S; Tavolari S; Brandi G
Anticancer Res; 2020 Jun; 40(6):3013-3030. PubMed ID: 32487595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
